W
hile a weight loss drug, Alli, has been authorized for sale free (without medical prescription) in the USA, research shows that consumers who are considering taking help for weight loss medication have more likely to move towards the continuation of bad eating habits and sedentary lifestyles.This effect would occur for two reasons.
The marketing of weight loss drug, usually presented as an easy and magical, undermines the incentive to adopt a healthy lifestyle.
Why bother to eat foods low in fat if the weight loss drug can fight fat ? The drugs also seem to weaken the beliefs of people in their ability to adopt a healthy lifestyle.
In a series of experiments and tests, researchers at Wharton and the University of Pennsylvania found that the supplements do not have the same reactions on lifestyle. Regardless of the actual effectiveness of the product, consumers' perceptions that the additions would require behaviour "supplementary" to yield results.
People tend to choose additions to "have faith" rather than relying on science demonstrations of their effectiveness, say the researchers, and they perceive these weight loss products as "natural" and thus could not interfere.
These results add to the debate on the regulation of markets for medicines and food supplements and on the role of advertising for drugs aimed directly at consumers.
Mention that Alli weight loss drug is a half-dose version of Xenical (orlistat). It blocks the absorption of some fat by the intestines. The marketing of the drug positioned as playing a role in a healthy lifestyle that includes menu planning and weight loss exercise.
Related Post :
Weight Loss Drugs
weight loss drugs, which are not specifically dedicated to weight loss, are also sometimes prescribed in specific cases
The Weight Loss Drugs, Xenical and Alli
Weight loss drugs efficiency and long-term side effects...
The Weight Loss Drugs, Meridia
This weight loss drug carries a risk of increased blood pressure...
The Weight Loss Drugs, Acomplia
The Acomplia weight loss drugs reduces system action of the brain responding to the cannabinoid system
